Alnylam Pharmaceuticals, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -145.0% | -145.0% | -23.4% |
| FY2022 | 714.9% | 714.9% | -31.9% |
| FY2023 | 199.5% | 199.5% | -11.5% |
| FY2024 | -414.6% | -414.6% | -6.6% |
| FY2025 | 39.8% | 39.8% | 6.3% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -145.0% | -145.0% | -23.4% |
| FY2022 | 714.9% | 714.9% | -31.9% |
| FY2023 | 199.5% | 199.5% | -11.5% |
| FY2024 | -414.6% | -414.6% | -6.6% |
| FY2025 | 39.8% | 39.8% | 6.3% |